Cancer
Celgene signs $1.5bn partnership with Immatics to fight cancer with engineered T-cell therapies
August 29, 2019Research and Development Cancer, Celgene, immatics, immunotherapy, pharma
Celgene and biopharma firm Immatics Biotechnologies have announced that they have entered a partnership valued at a potential $1.5 billion …
Sea snail chemical could be used as preventative treatment for bowel cancer, study shows
August 28, 2019Research and Development Australia, Cancer, bowel cancer, pharma, research
A chemical produced by Australian sea snails is showing promise as a potential treatment for cancer, according to researchers from …
AstraZeneca’s Imfinzi flops in advanced treatment-naive non-small cell lung cancer
August 21, 2019Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
New data have emerged illustrating that AstraZeneca’s anti-CTLA4 antibody Imfinzi (durvalumab) failed to meet its primary endpoint when used in …
Celgene’s Inrebic becomes second FDA-approved therapy for rare bone marrow disorder
August 19, 2019Sales and Marketing Cancer, Cerlgene, FDA, Inrebic, pharma, rare disease
Celgene is celebrating the approval in the US of its Janus kinase (JAK) 2 inhibitor Inrebic (fedratinib) in the treatment …
Roche’s cancer drug Rozlytrek scores double approval from FDA
August 16, 2019Medical Communications Cancer, Roche, Rozlytrek, lung cancer, oncology
The FDA has approved Roche’s Rozlytrek (entrectinib) as a treatment for adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). …
Lynparza extends progression-free survival in first-line advanced ovarian cancer, with or without BRCA mutations
August 14, 2019Research and Development AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma
New Phase 3 data has emerged on AstraZeneca and MSD’s Lynparza (olaparib), showing that the PARP inhibitor achieved its primary …
MSD teams up with Harvard University to discover novel immune system pathways to fight cancer
August 13, 2019Manufacturing and Production, Research and Development Cancer, Harvard, MSD, Merck, immuno-oncology, oncology, pharma
A new partnership between MSD and Harvard University hopes to combine the expertise of both parties to carve a path …
AstraZeneca’s Tagrisso improves overall survival in lung cancer in Phase 3 trial
August 9, 2019Medical Communications AstraZeneca, Cancer, Tagrisso, lung cancer, oncology, pharma
AstraZeneca has said its cancer drug Tagrisso significantly improved overall survival in a Phase 3 study of patients with lung …
Transgene terminates oncolytic IO combo trial in advanced liver cancer
August 8, 2019Research and Development Cancer, Transgene, clinical trials, liver cancer, pharma
Biotech firm Transgene has announced its decision to terminate a study investigating the efficacy of its oncolytic immunotherapy product Pexa-Vec …
Medicare will cover CAR-T therapies in United States
August 8, 2019Sales and Marketing CAR-T therapies, Cancer, Gilead, Kymriah, Medicare, Novartis, keytruda, pharma
Medicare will cover the cost of Novartis’ and Gilead’s CAR-T therapies Kymriah and Yescarta, the US Centers for Medicare and …
Keytruda/chemo combo recommended for first-line lung cancer via Cancer Drugs Fund
August 8, 2019Sales and Marketing CDF, Cancer, MSD, NHS, NICE, UK, keytruda, lung cancer, pharma
MSD’s Keytruda (pembrolizumab) has secured recommendation from NICE for inclusion on the Cancer Drugs Fund (CDF) in combination with chemotherapy …
NICE recommends Pierre Fabre’s Nerlynx in adjuvant HER2+ breast cancer
August 7, 2019Research and Development, Sales and Marketing Cancer, NCIE, NHS, Nerlynx, Pierre Fabre, UK, breast cancer
Pierre Fabre’s Nerlynx (neratinib) has been recommended by NICE as a new option for NHS patients with early hormone-receptor-positive, human …
Additional data for Boehringer’s Giotrif combo shows strong overall survival benefit in lung cancer sub-population
August 5, 2019Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, giotrif, lung cancer, pharma
German firm Boehringer Ingelheim has released new interim data from a real-world evidence study investigating the efficacy of Giotrif/Gilotrif (afatinib) …
Daiichi Sankyo’s Turalio becomes first FDA-approved therapy for rare tumour
August 5, 2019Sales and Marketing Cancer, Daiichi Sankyo, FDA, Turalio, US, pharma, rare cancer
Daiichi Sankyo has seen its CSF1R inhibitor Turalio (pexidartinib) approved by the FDA in the treatment of symptomatic tenosynovial giant …
Roche’s Tecentriq meets primary endpoint in Phase 3 bladder cancer trial
August 5, 2019Sales and Marketing Cancer, Roche, bladder cancer, immunotherapy, oncology, tecentriq
Roche has said its immunotherapy drug Tecentriq (Atezolizumab), when used in combination with platinum-based chemotherapy, significantly reduced the risk of …
Latest content
Five Facts about cardiovascular disease
